secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001104659-25-109732
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Q3 net loss $30.9M; plans sNDA for IGALMI at-home use in Q1 2026
------------------------------------------------------------------------

- Net revenue of $98K from IGALMI, down from $214K YoY; cost of goods sold fell to $11K.
- Net loss widened to $30.9M ($14.2M operating loss) from $13.7M loss a year ago; operating cash use $18.8M.
- R&D expense rose to $8.7M (up $3.6M) due to SERENITY At-Home trial; SG&A fell to $5.4M.
- Cash and equivalents $37.3M at Sep 30; raised $4.9M post-quarter via ATM.
- Plans sNDA submission in early Q1 2026 for IGALMI at-home agitation treatment; revised addressable market to 57-77M annual episodes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925109732/0001104659-25-109732-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925109732/tm2530979d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-109732

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer